Minneapolis, MNNCT06412497Now EnrollingIRB Ready

Severe Aplastic Anemia Clinical Trial in Minneapolis, MN

Access cutting-edge severe aplastic anemia treatment through this clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.

Sponsored by Masonic Cancer Center, University of Minnesota

Quick Self-Assessment

See if you qualify for this Minneapolis location

Preparing your pre-screening questions…

Expert Care in Minneapolis

Access severe aplastic anemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related severe aplastic anemia treatment provided free

Apply for This Minneapolis Location

Check if you qualify for this severe aplastic anemia clinical trial in Minneapolis, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Minneapolis

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Minneapolis site if eligible
  4. 4Begin participation

About This Severe Aplastic Anemia Study in Minneapolis

A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on age, presence of myelodysplasia and/or clonal hematopoiesis.

Sponsor: Masonic Cancer Center, University of Minnesota

Who Can Participate

Inclusion Criteria

Idiopathic Severe Aplastic Anemia (SAA), characterized by one of the following:
Refractory cytopenia(s), with 1+ of the following:
Platelets \<20,000/uL or transfusion dependent
Absolute neutrophil count \<500/uL without hematopoietic growth factor support
Absolute reticulocyte count \<60,000/uL AND bone marrow cellularity \<50% (with \< 30% residual hematopoietic cells)
Early myelodysplastic features (bone marrow (BM) blasts \<5%), without history of MDS/AML pre-treatment.
Idiopathic SAA with post-HCT graft failure (blood/marrow donor chimerism \<5%) requiring a 2nd allogeneic HCT
Paroxysmal Nocturnal Hemoglobinuria (PNH), including AA-PNH overlap syndrome, acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT), characterized by one of the following:
Refractory cytopenia(s), with 1+ of the following:
Platelets \<20,000/uL or transfusion dependent
Absolute neutrophil count \<500/uL without hematopoietic growth factor support
Absolute reticulocyte count \<60,000/uL or red cell transfusion dependent AND Bone marrow evidence of 1 to 3-lineage aplasia OR peripheral blood PNH clone \>/= 10%
Early myelodysplastic features (bone marrow (BM) blasts \<5%) without history of MDS/AML pre-treatment.
Idiopathic PNH, aPRCA, or aAT with post-HCT graft failure (blood/marrow donor chimerism \<5%) requiring a 2nd allogeneic HCT
Adequate organ function within 30 days of conditioning regimen

Exclusion Criteria

Pregnant, breastfeeding or intending to become pregnant during the study. Persons of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days of the start of treatment
Uncontrolled infection
Evidence of moderate or severe portal fibrosis or cirrhosis on biopsy
Known allergy to any of the study components
Prior radiation therapy deemed excessive by radiation therapist for proposed low dose TBI exposure on this protocol
Diagnosis of an inherited bone marrow failure disorder such as Fanconi anemia, Telomere biology disorder, or Schwachman-Diamond syndrome, unless reviewed by the principal investigator and deemed appropriate for this approach (e.g. GATA2 deficiency)
Advanced myelodysplastic syndrome (MDS; BM blasts \>5%) or acute myeloid leukemia
Psychiatric illness/social situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements
Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Minneapolis?

Yes, this clinical trial (NCT06412497) has an active research site in Minneapolis, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Severe Aplastic Anemia Treatment Options in Minneapolis, MN

If you're searching for severe aplastic anemia treatment options in Minneapolis, MN, this clinical trial (NCT06412497) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced severe aplastic anemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all severe aplastic anemia clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Minneapolis, MN

See all heart attack clinical trials recruiting in Minneapolis — not just this study.

Browse Heart Attack Trials in Minneapolis →

Browse More Trials by Condition

Heart Attack TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsAnemia TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Minneapolis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Minneapolis, MN